A multi-center,randomized, double-blind, placebo-controlled, phase 2, exploratory study to evaluate the effect of rufinamide on anxiety in patients with moderate to severe generalized anxiety disorder
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Rufinamide (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Synosia Therapeutics
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 07 Jun 2008 The expected completion date for this trial is now 1 Jan 2009, as reported by ClinicalTrials.gov.